<SEC-DOCUMENT>0001415889-25-010640.txt : 20250414
<SEC-HEADER>0001415889-25-010640.hdr.sgml : 20250414
<ACCEPTANCE-DATETIME>20250414181315
ACCESSION NUMBER:		0001415889-25-010640
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250414
DATE AS OF CHANGE:		20250414

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inventiva S.A.
		CENTRAL INDEX KEY:			0001756594
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91576
		FILM NUMBER:		25837047

	BUSINESS ADDRESS:	
		STREET 1:		50 RUE DE DIJON
		CITY:			DAIX
		STATE:			I0
		ZIP:			21121
		BUSINESS PHONE:		33380447500

	MAIL ADDRESS:	
		STREET 1:		50 RUE DE DIJON
		CITY:			DAIX
		STATE:			I0
		ZIP:			21121

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Andera Partners
		CENTRAL INDEX KEY:			0001757283
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		374 RUE SAINT ST HONORE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75001
		BUSINESS PHONE:		33-1-85-73-6603

	MAIL ADDRESS:	
		STREET 1:		374 RUE SAINT ST HONORE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75001
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001757283</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
	      <securitiesClassTitle>Ordinary Shares, nominal value Euro 0.01 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>10/17/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001756594</issuerCik>        <issuerName>Inventiva S.A.</issuerName>        <issuerCusip>46124U107</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>50 rue de Dijon</com:street1>
                    <com:city>Daix</com:city>
          <com:stateOrCountry>I0</com:stateOrCountry>
          <com:zipCode>21121 </com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	   				        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
		      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Andera Partners</reportingPersonName>



		 <citizenshipOrOrganization>I0</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>6148147.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>6148147.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6148147.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>6.5</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>



    <reportingPersonName>BioDiscovery 6 FPCI</reportingPersonName>



		 <citizenshipOrOrganization>I0</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>6148147.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>6148147.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6148147.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>6.5</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>



    <reportingPersonName>Stephane Bergez </reportingPersonName>



		 <citizenshipOrOrganization>I0</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>6148147.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>6148147.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6148147.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>6.5</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>



    <reportingPersonName>Francois Xavier Mauron</reportingPersonName>



		 <citizenshipOrOrganization>I0</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>6148147.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>6148147.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6148147.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>6.5</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>Inventiva S.A.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>50 rue de Dijon, Daix, I0, 21121 .</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>The names of the persons filing this report (collectively, the "Reporting Persons") are:

BioDiscovery 6 FPCI ("BioDiscovery 6")
Andera Partners ("Andera")
Stephane Bergez ("Bergez")
Francois Xavier Mauron ("Mauron")

The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>2 place de Rio de Janeiro
75008 Paris
France</principalBusinessOfficeOrResidenceAddress>        <citizenship>BioDiscovery 6	France
Andera			France
Bergez 			France
Mauron			France
</citizenship>      </item2>

        <item3>
		        <notApplicableFlag>Y</notApplicableFlag>

      </item3>



    <item4>
    <amountBeneficiallyOwned>Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference.

BioDiscovery 6 is the record holder of 6,148,147 ordinary shares. Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 are made by its management company, Andera. The managing partners of Andera are Bergez and Mauron. As a result, each of the Reporting Persons may be deemed to beneficially own the securities held by BioDiscovery 6.

CUSIP Number 46124U107 has been assigned to the American Depositary Shares ("ADS") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IVA". Each ADS represents one ordinary share of the Issuer. No CUSIP has been assigned to the Issuer's ordinary shares.  </amountBeneficiallyOwned>    <classPercent>Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. The percentage set forth in each row 11 is based upon 94,949,759 ordinary shares outstanding as of December 19, 2024, as reported in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission (the "SEC") on December 16, 2024.

</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference.</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference.</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference.</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference.</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>
	          <notApplicableFlag>Y</notApplicableFlag>


    </item5>


        <item6>
	  	  <notApplicableFlag>Y</notApplicableFlag>
		        </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>

      </item10>
    </items>

		<exhibitInfo>Exhibit 99.1	Joint Filing Agreement</exhibitInfo>

	    <signatureInformation>
      <reportingPersonName>Andera Partners</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Stephane Bergez </signature>
        <title>By Stephane Bergez, Managing Partner</title>
        <date>04/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>BioDiscovery 6 FPCI</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Stephane Bergez </signature>
        <title>By Andera Partners, its management company, By Stephane Bergez, Managing Partner</title>
        <date>04/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Stephane Bergez </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Stephane Bergez </signature>
        <title>Stephane Bergez </title>
        <date>04/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Francois Xavier Mauron</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Francois Xavier Mauron</signature>
        <title>Francois Xavier Mauron</title>
        <date>04/14/2025</date>
      </signatureDetails>

    </signatureInformation>



  </formData>


    </edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99-04142025_100413.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex-99-04142025_100413.htm</title></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin-top:0px; margin-bottom:16px; padding-left:36px" align="center">EXHIBIT 99.1</p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:36px" align="center">JOINT FILING AGREEMENT</p>
<p style="margin:0px; text-indent:36px">In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing the attached Schedule 13G (or any amendments thereto) relating to the ordinary shares of Inventiva S.A. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.</p>
<p style="margin:0px"><br></p>
<p style="margin:0px; text-indent:36px">IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as April 14, 2025.</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><b>Andera Partners</b></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:30px; float:left">By:</p>
<p style="margin:0px; text-indent:-2px"><u>/s/ Stephane Bergez</u></p>
<p style="margin:0px; text-indent:30px; clear:left">Name: Stephane Bergez</p>
<p style="margin:0px; text-indent:30px">Title: Managing Partner</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><b>BioDiscovery 6 FPCI</b></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:30px; float:left">By: </p>
<p style="margin:0px; text-indent:-2px">Andera Partners</p>
<p style="margin-top:0px; margin-bottom:-2px; width:30px; clear:left; float:left">Its: </p>
<p style="margin:0px; text-indent:-2px">Management Company</p>
<p style="margin:0px; clear:left"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:30px; float:left">By:</p>
<p style="margin:0px; text-indent:-2px"><u>/s/ Stephane Bergez</u></p>
<p style="margin:0px; text-indent:30px; clear:left">Name: Stephane Bergez</p>
<p style="margin:0px; text-indent:30px">Title: Managing Partner</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><b>Stephane Bergez</b></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><u>/s/ Stephane Bergez </u></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><b>Fran&ccedil;ois Xavier Mauron</b></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><u>/s/ Fran&ccedil;ois Xavier Mauron </u></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
